MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 23, Issue 8, Pages 625-633
Publisher
Bioscientifica
Online
2016-06-30
DOI
10.1530/erc-16-0117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post-transcriptional regulation of O6-methylguanine-DNA methyltransferase MGMT in glioblastomas
- (2017) Valya Ramakrishnan et al. Cancer Biomarkers
- O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
- (2015) T Walter et al. BRITISH JOURNAL OF CANCER
- Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms
- (2014) Anja Maria Schmitt et al. NEUROENDOCRINOLOGY
- In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing
- (2013) Simone Kreth et al. ACTA NEUROPATHOLOGICA
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
- (2013) Robert L. Fine et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g
- (2012) Véronique Quillien et al. CANCER
- Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
- (2012) G. J. Kitange et al. CLINICAL CANCER RESEARCH
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
- (2012) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
- (2012) Shinji Kohsaka et al. MOLECULAR CANCER THERAPEUTICS
- miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
- (2012) W. Zhang et al. NEURO-ONCOLOGY
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
- (2012) Marianne Pavel et al. NEUROENDOCRINOLOGY
- Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma
- (2012) Arne Christians et al. PLoS One
- Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
- (2012) Ingrid H. Olsen et al. TheScientificWorldJOURNAL
- Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy
- (2011) Staffan Welin et al. CANCER
- Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
- (2011) Miyuki Uno et al. Clinics
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
- (2009) Cosimo Durante et al. ENDOCRINE-RELATED CANCER
- Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
- (2009) Lucie Karayan-Tapon et al. JOURNAL OF NEURO-ONCOLOGY
- O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
- (2008) M. H. Kulke et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started